Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines

Hu, Zhidong; Jiang, Weimin; Gu, Ling; Qiao, Dan; Shu, Tsugumine; Lowrie, Douglas B.; Lu, Shuaiyao; Fan, Xiao‐Yong

doi:10.1007/s00109-019-01844-3

Cited by 13 publications

(6 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taken overall, these findings were consistent with the major roles of IFN-γ and multifunctional T cells in the protective immune response as previously described ( Cooper et al, 1993 ; Aagaard et al, 2009 ; Abel et al, 2010 ; Scriba et al, 2010 ; Sweeney et al, 2011 ; Green et al, 2013 ; Hu et al, 2019 ; Waeckerle-Men et al, 2022 ). We conclude that the association of Rv2299c with Ag85A in the DNA fusion vaccine provided an attractive starting point for the development of a multi-antigen DNA vaccine to boost BCG immunity without impairing the use of the current antigen-specific TB diagnostic tests.…”

Section: Discussionsupporting

confidence: 92%

“…They have proven successful in various animal models in treating and preventing cancer, autoimmunity, and infectious diseases ( Abdulhaqq and Weiner, 2008 ; Ojha and Prajapati, 2021 ). We and others have described several DNA vaccines that can confer immune protection against Mtb ( Fan et al, 2009 ; Wu et al, 2011 ; Kang et al, 2014 ; Xu et al, 2014 ; Ji et al, 2016 ; Hu et al, 2019 ). Consequently, DNA vaccines are especially promising candidates for clinical development; however, the efficacy of DNA vaccines expressing only one antigen of Mtb is limited ( Kamath et al, 1999 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Heterologous prime-boost BCG with DNA vaccine expressing fusion antigens Rv2299c and Ag85A improves protective efficacy against Mycobacterium tuberculosis in mice

et al. 2022

Front. Microbiol.

Self Cite

View full text Add to dashboard Cite

The development of heterologous prime-boost regimens utilizing Bacille Calmette–Guerin (BCG) as the priming vaccine is a promising approach to improve the efficacy of vaccination against tuberculosis (TB). In this study, we examined the ability of a DNA vaccine that expressed a fusion of antigens Rv2299c and Ag85A to boost BCG immunity and protection against Mycobacterium tuberculosis (Mtb) in Balb/c mice. The fusion DNA vaccine was moderately immunogenic and afforded some protection when used on its own. After a priming BCG vaccination, the DNA boost significantly amplified Th1-type cell-mediated immunity compared to that resulting from either BCG or DNA immunization. In the DNA-boosted mice, Ag-specific CD4+ and CD8+ T cells that were mono-positive for IFN-γ alone were the most prominently expanded in infected lungs. The protective efficacy afforded by BCG against challenge infection was greatly improved by the DNA boost; bacterial loads were significantly reduced in both spleen and lung and histological damage in the lung was less. The use of a DNA vaccine containing the fusion antigens Rv2299c and Ag85A to boost BCG may be a good choice for the rational design of an efficient vaccination strategy against TB.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Heterologous prime-boost BCG with DNA vaccine expressing fusion antigens Rv2299c and Ag85A improves protective efficacy against Mycobacterium tuberculosis in mice

et al. 2022

Front. Microbiol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Evaluation of the safety and immunogenicity of an intranasally administered replication-competent SeV—vectored HIV Type 1 gag protein vaccine demonstrated induction of potent T-cell and antibody responses in prime-boost regimens [ 86 , 99 ]. SeV has also been used as the backbone for vaccines against tuberculosis [ 87 , 100 ] and respiratory syncytial virus (RSV) [ 88 , 89 ]. RSV, also called human orthopneumovirus, is a major cause of lower respiratory tract infections and hospital visits during infancy and childhood.…”

Section: Vector Vaccinesmentioning

confidence: 99%

The Challenges of Vaccine Development against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector

Zaichuk¹,

Nechipurenko

Adzhubey

et al. 2020

Mol Biol

View full text Add to dashboard Cite

To design an effective and safe vaccine against betacoronaviruses, it is necessary to use their evolutionarily conservative antigenic determinants that will elicit the combination of strong humoral and cellmediated immune responses. Targeting such determinants minimizes the risk of antibody-dependent enhancement of viral infection. This phenomenon was observed in animal trials of experimental vaccines against SARS-CoV-1 and MERS-CoV that were developed based on inactivated coronavirus or vector constructs expressing the spike protein (S) of the virion. The substitution and glycosylation of certain amino acids in the antigenic determinants of the S-protein, as well as its conformational changes, can lead to the same effect in a new experimental vaccine against SARS-CoV-2. Using more conservative structural and accessory viral proteins for the vaccine antigenic determinants will help to avoid this problem. This review outlines approaches for developing vaccines against the new SARS-CoV-2 coronavirus that are based on non-pathogenic viral vectors. For efficient prevention of infections caused by respiratory pathogens the ability of the vaccine to stimulate mucosal immunity in the respiratory tract is important. Such a vaccine can be developed using non-pathogenic Sendai virus vector, since it can be administered intranasally and induce a mucosal immune response that strengthens the antiviral barrier in the respiratory tract and provides reliable protection against infection.

show abstract

“…Therefore, this vaccine may be used to optimize the systemic BCG-induced immune protection against Mtb infection ( 104 ). This immunization strategy was further optimized in combination with recombinant DNA vaccines for improved protective efficacy ( 105 ).…”

Section: Recombinant Virus-vectored Tb Vaccinesmentioning

confidence: 99%

Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development

Lowrie

et al. 2022

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

Tuberculosis (TB), caused by respiratory infection with Mycobacterium tuberculosis, remains a major global health threat. The only licensed TB vaccine, the one-hundred-year-old Bacille Calmette-Guérin has variable efficacy and often provides poor protection against adult pulmonary TB, the transmissible form of the disease. Thus, the lack of an optimal TB vaccine is one of the key barriers to TB control. Recently, the development of highly efficacious COVID-19 vaccines within one year accelerated the vaccine development process in human use, with the notable example of mRNA vaccines and adenovirus-vectored vaccines, and increased the public acceptance of the concept of the controlled human challenge model. In the TB vaccine field, recent progress also facilitated the deployment of an effective TB vaccine. In this review, we provide an update on the current virus-vectored TB vaccine pipeline and summarize the latest findings that might facilitate TB vaccine development. In detail, on the one hand, we provide a systematic literature review of the virus-vectored TB vaccines are in clinical trials, and other promising candidate vaccines at an earlier stage of development are being evaluated in preclinical animal models. These research sharply increase the likelihood of finding a more effective TB vaccine in the near future. On the other hand, we provide an update on the latest tools and concept that facilitating TB vaccine research development. We propose that a pre-requisite for successful development may be a better understanding of both the lung-resident memory T cell-mediated mucosal immunity and the trained immunity of phagocytic cells. Such knowledge could reveal novel targets and result in the innovative vaccine designs that may be needed for a quantum leap forward in vaccine efficacy. We also summarized the research on controlled human infection and ultra-low-dose aerosol infection murine models, which may provide more realistic assessments of vaccine utility at earlier stages. In addition, we believe that the success in the ongoing efforts to identify correlates of protection would be a game-changer for streamlining the triage of multiple next-generation TB vaccine candidates. Thus, with more advanced knowledge of TB vaccine research, we remain hopeful that a more effective TB vaccine will eventually be developed in the near future.

show abstract

Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines

Cited by 13 publications

References 50 publications

Heterologous prime-boost BCG with DNA vaccine expressing fusion antigens Rv2299c and Ag85A improves protective efficacy against Mycobacterium tuberculosis in mice

Heterologous prime-boost BCG with DNA vaccine expressing fusion antigens Rv2299c and Ag85A improves protective efficacy against Mycobacterium tuberculosis in mice

The Challenges of Vaccine Development against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector

Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development

Contact Info

Product

Resources

About